01/17 | RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial E.. | CI |
01/17 | Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer D.. | MT |
01/17 | Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating R.. | EQ |
2022 | Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVAfor Pati.. | AQ |
2022 | Acer Therapeutics' Olpruva Approved by FDA, Triggers Availability of $42.5 Million Loan | MT |
2022 | Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ .. | AQ |
2022 | Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva f.. | CI |
2022 | Relief Therapeutics, Acer Therapeutics Win US FDA Nod For Urea Cycle Disorders Treatmen.. | MT |
2022 | Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 wit.. | EQ |
2022 | Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ .. | EQ |
2022 | Acer Therapeutics Gets FDA Approval for Lead Drug Candidate Olpruva | DJ |
2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definiti.. | AQ |
2022 | Relief Therapeutics, NRx Pharmaceuticals Settle Litigation for Aviptadil Development Pr.. | MT |
2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definiti.. | EQ |
2022 | Relief Therapeutics Holding AG (SWX:RLF) acquired ZY.. | CI |
2022 | Relief Therapeutics to Participate in January Investor Meetings | EQ |
2022 | Swiss Biopharmaceutical Relief Therapeutics to Issue New Shares | MT |
2022 | Relief Therapeutics Announces Issuance of Shares from Authorized Capital | EQ |
2022 | Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer | CI |
2022 | Relief Therapeutics Holding AG Appoints Jack Weinstein as Chief Executive Officer | CI |
2022 | Relief Therapeutics Names New CEO, CFO | MT |
2022 | Relief Therapeutics Announces Executive Leadership Team Changes | EQ |
2022 | APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the .. | EQ |
2022 | Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 wit.. | EQ |
2022 | Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute | MT |
2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Defi.. | EQ |
2022 | An unknown buyer entered into a Asset Purchase Agreement to acquire ZYESAMI of NRx Phar.. | CI |
2022 | Relief Therapeutics, NRx Further Extend Stay of Pending Aviptadil Dispute | MT |
2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay .. | EQ |
2022 | Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation .. | CI |
2022 | Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data | MT |
2022 | Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 .. | EQ |
2022 | Relief Therapeutics, NRx Extend Stay For Pending Aviptadil Dispute | MT |
2022 | RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pendi.. | EQ |
2022 | Relief Therapeutics Seeks Reverse Split, Ratio Change Amid Move to NASDAQ | MT |
2022 | Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with t.. | EQ |
2022 | RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer | CI |
2022 | Relief Therapeutics Names New COO | MT |
2022 | Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer | EQ |
2022 | Switzerland's Relief Therapeutics Rolls Out PKU GOLIKE in US | MT |
2022 | Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE | CI |
2022 | Relief Announces U.S. Launch of PKU GOLIKE | EQ |
2022 | Relief Therapeutics Chooses Exclusive US Distributor For PKU GOLIKE | MT |
2022 | Relief Therapeutics Holding Ag Announces Exclusive Distributor for Pku Golike in the U... | CI |
2022 | Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. | EQ |
2022 | Relief Therapeutics Partner Acer To Secure US Patent For Phenylbutyrate-Sodium Benzoate.. | MT |
2022 | Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US.. | EQ |
2022 | Relief Therapeutics Gets US Approval to Launch Pilot Trial For Skin Disease Treatment | MT |
2022 | Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator.. | CI |
2022 | Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated .. | EQ |
2022 | Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30.. | CI |
2022 | Relief Therapeutics Posts Wider Attributable Loss In H1 | MT |
2022 | Relief Reports Half-Year 2022 Results and Provides Corporate Update | EQ |
2022 | Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum | EQ |
2022 | Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment.. | EQ |
2022 | Switzerland's Relief Therapeutics Seeks To List American Depositary Shares On NASDAQ | MT |
2022 | Relief Therapeutics files registration statement on form F-1 with the U.S. Securities a.. | EQ |
2022 | Relief Therapeutics Holding AG has filed an IPO. | CI |
2022 | NRx Pharmaceuticals, Relief Therapeutics Reach Tentative Settlement Over Zyesami Litiga.. | MT |
2022 | Relief Therapeutics, NRx Pharmaceuticals Secure Tentative Settlement Over Aviptadil Dis.. | MT |
2022 | Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlem.. | EQ |
2022 | Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access | EQ |
2022 | Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access,.. | CI |
2022 | Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Gra.. | AQ |
2022 | Acer Therapeutics, Relief Therapeutics Say EU Grants Orphan Drug Designation to ACER-00.. | MT |
2022 | RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Co.. | CI |
2022 | Relief Therapeutics Partner Acer Gets EU Orphan Drug Designation For Maple Syrup Urine .. | MT |
2022 | Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Gra.. | EQ |
2022 | Relief Therapeutics : Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance fo.. | PU |
2022 | Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for .. | CI |
2022 | Relief Therapeutics' New Formulation For Lung Disease Drug Shows Clinical Significant I.. | MT |
2022 | Relief Therapeutics : Announces Promising Initial Stability Data on a New Formulation of R.. | PU |
2022 | Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of .. | EQ |
2022 | Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Res.. | CI |
2022 | Acer Therapeutics : FDA Accepts Resubmitted NDA for ACER-001 | DJ |